Trial · NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

NCT02441218, Phase 3, Completed, Institut de Recherches Internationales Servier; results first posted 2015-06-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study. Trials, record NCT02441218. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02441218

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
NCT number: NCT02441218
Status: Completed
Phases: Phase 3
Enrollment: 6,505 participants, actual
Lead sponsor: Institut de Recherches Internationales Servier
Conditions: Chronic Heart Failure
Interventions: Ivabradine, Placebo
First posted: 2015-05-12
Last updated: 2020-01-03
Other registries' IDs: eudract:2006-000708-18
Results first posted: 2015-06-29
Limitations and caveats: The section Other Adverse Events (Not including serious) has been completed by the sponsor to include only the Non Serious Adverse Events emergent on treatment during the study.

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.	All over the study (up to 42 months).	Number of patients having experienced the Primary Composite Endpoint.
Secondary	Cardiovascular Death	From the date of randomization until the date of death, up to 42 months	Component of the primary composite endpoint
Secondary	Hospitalisation for Worsening Heart Failure	From the date of randomization to the date of first documented hospitalisation, up to 42 months
Secondary	All-cause Mortality	From the date of randomisation to death, up to 42 months.
Secondary	Death From Heart Failure	From the date of randomisation to death, up to 42 months.	Component of cardiovascular death
Secondary	Hospitalisation for Any Cause	From the date of randomisation to the date of first documented hospitalisation, up to 42 months
Secondary	Hospitalisation for Cardiovascular Reason	From the date of randomisation to the first documented hospitalisation, up to 42 months
Secondary	Unplanned Hospitalisation for Any Cause	From the date of randomisation to the first documented hospitalisation, up to 42 months
Secondary	Unplanned Hospitalisation for CV Reason	From the date of randomisation to the first documented hospitalisation, up to 42 months.
Secondary	Secondary Composite Endpoint	From the date of randomisation to the date of the first event, up to 42 months	CV death, hospitalisation for worsening HF or hospitalisation for non-fatal myocardial infarction

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.	All over the study (up to 42 months).	participants	NUMBER
SECONDARY	Cardiovascular Death	From the date of randomization until the date of death, up to 42 months	participants	NUMBER
SECONDARY	Hospitalisation for Worsening Heart Failure	From the date of randomization to the date of first documented hospitalisation, up to 42 months	participants	NUMBER
SECONDARY	All-cause Mortality	From the date of randomisation to death, up to 42 months.	participants	NUMBER
SECONDARY	Death From Heart Failure	From the date of randomisation to death, up to 42 months.	participants	NUMBER
SECONDARY	Hospitalisation for Any Cause	From the date of randomisation to the date of first documented hospitalisation, up to 42 months	participants	NUMBER
SECONDARY	Hospitalisation for Cardiovascular Reason	From the date of randomisation to the first documented hospitalisation, up to 42 months	participants	NUMBER
SECONDARY	Unplanned Hospitalisation for Any Cause	From the date of randomisation to the first documented hospitalisation, up to 42 months	participants	NUMBER
SECONDARY	Unplanned Hospitalisation for CV Reason	From the date of randomisation to the first documented hospitalisation, up to 42 months.	participants	NUMBER
SECONDARY	Secondary Composite Endpoint	From the date of randomisation to the date of the first event, up to 42 months	participants	NUMBER

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.	Ivabradine	793	participants
Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.	Placebo	937	participants
Cardiovascular Death	Ivabradine	449	participants
Cardiovascular Death	Placebo	491	participants
Hospitalisation for Worsening Heart Failure	Ivabradine	514	participants
Hospitalisation for Worsening Heart Failure	Placebo	672	participants
All-cause Mortality	Ivabradine	503	participants
All-cause Mortality	Placebo	552	participants
Death From Heart Failure	Ivabradine	113	participants
Death From Heart Failure	Placebo	151	participants

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ivabradine	3,241
Overall Study	STARTED	Placebo	3,264
Overall Study	COMPLETED	Ivabradine	2,663
Overall Study	COMPLETED	Placebo	2,652
Overall Study	NOT COMPLETED	Ivabradine	578
Overall Study	NOT COMPLETED	Placebo	612

Source ClinicalTrials.gov

Adverse events1,416

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Ivabradine	91	3,232	93
other	Anaemia	Blood and lymphatic system disorders	Placebo	92	3,260	96
other	Angina pectoris	Cardiac disorders	Ivabradine	85	3,232	97
other	Angina pectoris	Cardiac disorders	Placebo	93	3,260	109
other	Atrial fibrillation	Cardiac disorders	Ivabradine	161	3,232	176
other	Atrial fibrillation	Cardiac disorders	Placebo	123	3,260	138
other	Atrioventricular block first degree	Cardiac disorders	Ivabradine	35	3,232	38
other	Atrioventricular block first degree	Cardiac disorders	Placebo	36	3,260	42
other	Bradycardia	Cardiac disorders	Ivabradine	134	3,232	142
other	Bradycardia	Cardiac disorders	Placebo	26	3,260	30

1 to 10 of 1,416Source ClinicalTrials.gov

See all 1,416 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ivabradine
Total, all-cause mortality	Placebo
Total, other adverse events	Ivabradine	2,062	3,232
Total, other adverse events	Placebo	2,020	3,260
Total, serious adverse events	Ivabradine	1,369	3,232
Total, serious adverse events	Placebo	1,481	3,260

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20801495	RESULT	PubMed
20801500	RESULT	PubMed
28205056	DERIVED	PubMed
32580655	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons11

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ivabradine vs Placebo: Hospitalisation for Worsening Heart Failure	Trial comparisons
Ivabradine vs Placebo: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.	Trial comparisons
Ivabradine vs Placebo: Unplanned Hospitalisation for CV Reason	Trial comparisons
Ivabradine vs Placebo: Death From Heart Failure	Trial comparisons
Ivabradine vs Placebo: Hospitalisation for Cardiovascular Reason	Trial comparisons
Ivabradine vs Placebo: Hospitalisation for Any Cause	Trial comparisons
Ivabradine vs Placebo: Secondary Composite Endpoint	Trial comparisons
Ivabradine vs Placebo: Cardiovascular Death	Trial comparisons
Ivabradine vs Placebo: All-cause Mortality	Trial comparisons
Ivabradine vs Placebo: Unplanned Hospitalisation for Any Cause	Trial comparisons

1 to 10 of 11

See all 11 trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02441218

GET https://conductscience.org/api/trials/v1/NCT02441218/events?page=2

API reference For AI assistants